Figure 4.
(A) Postinjection time point radiant efficiencies of tumor region of osteosarcoma tumor-bearing NSG mice after tail vein injection of Cy5.5-labeled HPMA–CHP, HPMA–SCHP, or CHP; (B) AUC and t1/2 of compounds at the tumor, calculated using noncompartmental pharmacokinetic analysis; and (C) radiant efficiencies at postinjection time points with corresponding comparative p values (mean ± SD, N = 6, *p < 0.05, **p < 0.01, and ***p < 0.001).